2021
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease. Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.Peer-Reviewed Original ResearchConceptsDurable polymer everolimus-eluting stentsDrug-eluting stentsTarget lesion revascularizationAntiproliferative drug deliveryChronic coronary syndromeVessel myocardial infarctionLesion revascularizationCoronary syndromeLesion failureMyocardial infarctionDrug-Eluting Stent ImplantationTarget vessel myocardial infarctionLong-term clinical outcomesDP-EES groupPrimary end pointTarget lesion failureSmooth muscle cell proliferationPercutaneous coronary interventionSingle-blind trialCoronary artery diseaseEverolimus-eluting stentsMuscle cell proliferationLong-term inflammatory responseDrug eluting stentsCardiovascular death
2020
Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study
Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. Journal Of Endovascular Therapy 2020, 27: 473-480. PMID: 32242768, PMCID: PMC7288854, DOI: 10.1177/1526602820914598.Peer-Reviewed Original ResearchConceptsPeripheral artery diseasePeripheral intravascular lithotripsyIntravascular lithotripsyResidual stenosisAcute gainObservational studyChronic limb-threatening ischemiaSingle-arm observational studyBalloon-based technologiesHigher acute gainMean residual stenosisLimb-threatening ischemiaLower limb arteriesEnd of procedureSevere arterial calcificationLow residual stenosisReal-world studyAngiographic complicationsDistal embolizationHospital dischargeIII studyArtery diseaseThrombotic eventsEndovascular treatmentLimb arteries
2019
Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation
Krittanawong C, Kumar A, Wang Z, Johnson KW, Rastogi U, Narasimhan B, Kaplin S, Virk HUH, Baber U, Tang W, Lansky AJ, Stone GW. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2019, 125: 251-257. PMID: 31759517, DOI: 10.1016/j.amjcard.2019.10.014.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationBaseline heart failureAortic valve implantationHeart failureAdditional independent predictorsHospital mortalityEjection fractionIndependent predictorsValve implantationPresence of HFReduced ejection fractionSevere aortic stenosisIn-Hospital MortalityPredictors of mortalityPotential baseline confoundersAortic valve stenosisICD-9 codesAbsence of depressionTAVI patientsHF patientsAortic stenosisValve stenosisLiver diseaseMultivariable analysisPatient selectionSafety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses
Ali ZA, Nef H, Escaned J, Werner N, Banning AP, Hill JM, De Bruyne B, Montorfano M, Lefevre T, Stone GW, Crowley A, Matsumura M, Maehara A, Lansky AJ, Fajadet J, Di Mario C. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. Circulation Cardiovascular Interventions 2019, 12: e008434. PMID: 31553205, DOI: 10.1161/circinterventions.119.008434.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac CatheterizationCoronary AngiographyCoronary StenosisEuropeFemaleHumansLithotripsyMaleMiddle AgedPatient SafetyPercutaneous Coronary InterventionProspective StudiesRisk FactorsSeverity of Illness IndexStentsTime FactorsTomography, Optical CoherenceTreatment OutcomeUnited StatesVascular CalcificationConceptsSevere coronary artery calcificationCoronary artery calcificationMajor adverse cardiac eventsAdverse cardiac eventsPrimary end pointIntravascular lithotripsyOptical coherence tomographyCardiac eventsStent implantationPlaque fractureHospital major adverse cardiac eventsNon-Q-wave myocardial infarctionOptical coherence tomography substudyIndependent clinical events committeeCoherence tomographyDrug-eluting stent implantationEnd pointCoronary intravascular lithotripsyClinical events committeeHigh procedural successIndependent core laboratoryAcute luminal gainPost-approval studiesMechanism of actionCalcium fractureThe Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry
Gul B, Lansky A, Budoff MJ, Sharp D, Maniet B, Herman L, Kuo JZ, Huang L, Monane M, Ladapo JA. The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. Journal Of Women's Health 2019, 28: 728-735. PMID: 30653377, PMCID: PMC6537117, DOI: 10.1089/jwh.2018.7203.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseFurther cardiac evaluationCardiac evaluationArtery diseaseClinical utilityStable obstructive coronary artery diseaseMajor adverse cardiac eventsMedian age 57 yearsMedian body mass indexAdverse cardiac eventsAge 57 yearsManagement of womenBody mass indexCommunity-based registryPrimary care practicesPrecision medicine testsGene expression scoreCardiac referralHypertension presentSymptoms SuggestiveCardiac eventsClinical characteristicsMass indexStudy cohort
2018
Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II
Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheterization And Cardiovascular Interventions 2018, 93: 335-342. PMID: 30474206, DOI: 10.1002/ccd.27943.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overEuropeFemaleFemoral ArteryHumansLithotripsyMaleMiddle AgedNew ZealandPeripheral Arterial DiseasePopliteal ArteryProgression-Free SurvivalProspective StudiesRetreatmentRisk FactorsSeverity of Illness IndexTime FactorsUltrasonic TherapyVascular CalcificationVascular PatencyConceptsMajor adverse eventsIntravascular lithotripsyPrimary patencyDuplex ultrasonographyPAD IIAcute procedure successFinal residual stenosisPrimary effectiveness endpointPrimary safety endpointKey secondary endpointPeripheral arterial stenosisMulti-center studySonic pressure wavesMechanism of actionCompelling safetyEffectiveness endpointAnti-proliferative therapiesSafety endpointSecondary endpointsVascular complicationsAdverse eventsFemoropopliteal lesionsResidual stenosisPrimary outcomeAcute gainCerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need?
Pagnesi M, Regazzoli D, Ancona MB, Mangieri A, Lanzillo G, Giannini F, Buzzatti N, Prendergast BD, Kodali S, Lansky AJ, Colombo A, Latib A. Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions An Unaddressed and Unmet Clinical Need? JACC Cardiovascular Interventions 2018, 11: 517-528. PMID: 29566796, DOI: 10.1016/j.jcin.2017.12.018.Peer-Reviewed Original ResearchConceptsTranscatheter mitral valve interventionsCerebral embolic riskMitral valve interventionMV proceduresEmbolic riskValve interventionHeart interventionsProcedure-related adverse eventsPatient-related factorsStructural heart interventionsReal clinical issueMV interventionAdverse eventsEmbolic injuryMV diseaseUnmet ClinicalMV anatomyClinical issuesAvailable evidenceInterventionRiskSystematic assessmentClinicalInjuryAvailable dataComparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China
Zhang H, Mu L, Hu S, Nallamothu BK, Lansky AJ, Xu B, Bouras G, Cohen DJ, Spertus JA, Masoudi FA, Curtis JP, Gao R, Ge J, Yang Y, Li J, Li X, Zheng X, Li Y, Krumholz HM, Jiang L. Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. JAMA Internal Medicine 2018, 178: 239-247. PMID: 29340571, PMCID: PMC5838612, DOI: 10.1001/jamainternmed.2017.7821.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChinaCoronary AngiographyCoronary StenosisCoronary VesselsCross-Sectional StudiesFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPercutaneous Coronary InterventionPractice Patterns, Physicians'Predictive Value of TestsProspective StudiesRisk AssessmentSeverity of Illness IndexTime FactorsConceptsPhysician visual assessmentPercutaneous coronary interventionAcute myocardial infarctionQuantitative coronary angiographyStenosis severityCoronary angiographyMean agePCI studiesMean percent diameter stenosisIndependent core laboratoryPercent diameter stenosisCross-sectional studyNon-AMI patientsStandard clinical practiceFractional flow reserveSubset of participantsQCA assessmentCoronary revascularizationMore stenosisCoronary interventionCoronary lesionsChina PatientCoronary angiogramDiameter stenosisMyocardial infarction
2016
Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial)
Lansky AJ, Brown D, Pena C, Pietras CG, Parise H, Ng VG, Meller S, Abrams KJ, Cleman M, Margolis P, Petrossian G, Brickman AM, Voros S, Moses J, Forrest JK. Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Neuro-TAVI Trial). The American Journal Of Cardiology 2016, 118: 1519-1526. PMID: 27645761, DOI: 10.1016/j.amjcard.2016.08.013.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAortic ValveAortic Valve StenosisBrainBrain IschemiaDiffusion Magnetic Resonance ImagingFemaleFollow-Up StudiesHumansIncidenceIntracranial EmbolismMalePostoperative ComplicationsPrognosisProspective StudiesRisk AssessmentRisk FactorsSurvival RateTranscatheter Aortic Valve ReplacementUnited StatesConceptsTranscatheter aortic valve implantationAortic valve implantationNeurologic injuryValve implantationNeurologic impairmentMagnetic resonance imaging lesionsCognitive AssessmentMontreal Cognitive Assessment scoreCerebral ischemic lesionsNew neurologic impairmentSubclinical cerebral infarctsDiffusion-weighted magnetic resonance imagingTotal lesion volumeCognitive Assessment scoreMontreal Cognitive AssessmentMagnetic resonance imagingCerebral embolizationCerebral infarctsNeurologic complicationsCerebral infarctionImaging lesionsMost patientsOvert strokeConsecutive patientsIschemic lesionsTranscatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials)
Forrest JK, Adams DH, Popma JJ, Reardon MJ, Deeb GM, Yakubov SJ, Hermiller JB, Huang J, Skelding KA, Lansky A. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). The American Journal Of Cardiology 2016, 118: 396-402. PMID: 27346591, DOI: 10.1016/j.amjcard.2016.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisCause of DeathComorbidityFemaleFrail ElderlyHumansIncidenceMaleMortalityPostoperative ComplicationsPostoperative HemorrhageSeverity of Illness IndexSex FactorsStrokeTranscatheter Aortic Valve ReplacementTreatment OutcomeVentricular Dysfunction, LeftConceptsTranscatheter aortic valve replacementAortic valve replacementCoreValve prosthesisValve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementLeft ventricular systolic functionWomen Versus MenMajor vascular complicationsSymptomatic aortic stenosisIncidence of strokeProcedure-related complicationsVentricular systolic functionCoronary artery diseaseLife-threatening bleedsSignificant baseline differencesGender-related differencesCause mortalityVascular complicationsBaseline characteristicsPatient characteristicsPrevious strokeSystolic functionAortic stenosisArtery disease
2015
Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)
Prasad A, Gersh BJ, Mehran R, Brodie BR, Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R, Guagliumi G, Dudek D, Stone GW. Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). JACC Cardiovascular Interventions 2015, 8: 1966-1974. PMID: 26738667, DOI: 10.1016/j.jcin.2015.08.031.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCoronary CirculationDrug-Eluting StentsFemaleHumansMaleMetalsMicrocirculationMiddle AgedMyocardial InfarctionMyocardial Perfusion ImagingPercutaneous Coronary InterventionProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsStentsTime FactorsTime-to-TreatmentTreatment OutcomeConceptsPrimary percutaneous coronary interventionMyocardial blush gradePrimary PCIHORIZONS-AMI trialMBG 0/1Balloon timeIndependent predictorsAnterior infarctionMyocardial perfusionST-segment elevation myocardial infarction (STEMI) patientsST-segment elevation myocardial infarctionHigher clinical risk profileElevation myocardial infarction patientsMyocardial Infarction (TIMI) risk scoreClinical risk profileMechanical reperfusion therapyReference vessel diameterElevation myocardial infarctionPercutaneous coronary interventionST-segment elevationEpicardial blood flowMinimum lumen diameterMyocardial infarction patientsMicrovascular reperfusionBlush gradeWill this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents.
Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention 2015, 11: 364-5. PMID: 26196757, DOI: 10.4244/eijv11i3a71.Peer-Reviewed Original ResearchSafety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.
Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015, 11: 75-84. PMID: 25868876, DOI: 10.4244/eijy15m04_01.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlloysAortic ValveAortic Valve StenosisBrain IschemiaBrazilCardiac CatheterizationCognitionCognition DisordersDiffusion Magnetic Resonance ImagingEmbolic Protection DevicesEuropeFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIntracranial EmbolismMalePredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTreatment OutcomeUltrasonography, Doppler, TranscranialConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementNew cerebral ischemic lesionsCerebral diffusion-weighted magnetic resonance imagingCerebral ischemic lesionsDays post procedurePrimary safety endpointDiffusion-weighted magnetic resonance imagingMajor cerebral arteriesTotal lesion volumeMagnetic resonance imagingSafety endpointIschemic lesionsTAVR proceduresCerebral arteryCerebral circulationConsecutive subjectsPost procedureAortic archHistorical controlsLesion volumeResonance imagingDW-MRIPatients
2014
The DENALI Trial: An Interim Analysis of a Prospective, Multicenter Study of the Denali Retrievable Inferior Vena Cava Filter
Stavropoulos SW, Sing RF, Elmasri F, Silver MJ, Powell A, Lynch FC, Aal AK, Lansky AJ, Settlage RA, Muhs BE, Investigators D. The DENALI Trial: An Interim Analysis of a Prospective, Multicenter Study of the Denali Retrievable Inferior Vena Cava Filter. Journal Of Vascular And Interventional Radiology 2014, 25: 1497-1505.e1. PMID: 25066514, DOI: 10.1016/j.jvir.2014.07.001.Peer-Reviewed Original ResearchConceptsInferior vena cava filterRetrievable inferior vena cava filtersTechnical success ratePulmonary embolismVena cava filtersFilter placementIVC filtersCava filtersClinical successFilter retrievalPrimary study endpointRecurrent pulmonary embolismDeep vein thrombosisMulticenter clinical studyRetrievable IVC filtersSuccess ratePresent interim reportTemporary indicationsCaval interruptionVein thrombosisStudy endpointFilter fractureMulticenter studyFilter implantationClinical studies
2013
Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit
Meller SM, Baumbach A, Voros S, Mullen M, Lansky AJ. Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit. BMC Medicine 2013, 11: 257. PMID: 24330754, PMCID: PMC4029193, DOI: 10.1186/1741-7015-11-257.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLesion volumeCerebral eventsValve implantationNew lesionsClinical studiesSurrogate endpointsAppropriate endpointsPrimary efficacy endpointDiffusion-weighted magnetic resonance imagingCerebral protection devicesUseful surrogate endpointTotal lesion volumeMagnetic resonance imagingSample size limitationsEfficacy endpointClinical outcomesDevice successOngoing trialsNeurological protectionClinical eventsResonance imagingMRI valuesConsensus opinionFirst-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)
Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries). JACC Cardiovascular Interventions 2013, 6: 1026-1034. PMID: 24055443, DOI: 10.1016/j.jcin.2013.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAdultAgedAged, 80 and overAngina, StableAngina, UnstableAustraliaBelgiumCardiovascular AgentsChromium AlloysCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary VesselsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionNeointimaNew ZealandPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolymersProspective StudiesProsthesis DesignSeverity of Illness IndexSirolimusTime FactorsTomography, Optical CoherenceTreatment OutcomeUltrasonography, InterventionalConceptsStent late lumen lossLate lumen lossSirolimus-eluting stentsOptical coherence tomographyIntravascular ultrasoundMajor adverse cardiac eventsSymptomatic coronary artery diseaseCoherence tomographyComplete strut coverageNeointimal volume obstructionUnderwent repeat angiographyAdverse cardiac eventsDual antiplatelet therapyCoronary artery diseaseUnstable angina pectorisDrug-eluting stentsLong-term riskAntiplatelet therapyVolume obstructionCardiac eventsRepeat angiographyAdverse eventsAngina pectorisArtery diseaseI trial
2012
Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial
Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ, for the PREDICT Investigators. Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial. Journal Of Cardiovascular Translational Research 2012, 5: 366-374. PMID: 22396313, PMCID: PMC3349850, DOI: 10.1007/s12265-012-9353-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleGene Expression RegulationGenetic Predisposition to DiseaseGenetic TestingHumansIschemic Attack, TransientLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPhenotypePredictive Value of TestsPrognosisProspective StudiesReproducibility of ResultsRisk AssessmentRisk FactorsStrokeTime FactorsUnited StatesConceptsMajor adverse cardiovascular eventsCoronary artery diseaseObstructive coronary artery diseaseGene expression scoreAdverse cardiovascular eventsCardiovascular eventsArtery diseaseClinical risk scoreGroup of patientsNegative predictive valueGene expression testingNondiabetic patientsPREDICT trialAngiography patientsGES groupPREDICT studyRisk scorePatientsPredictive valueExpression scoreRevascularizationEvent ratesDiseaseMonthsExpression testingPrognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens
Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation Cardiovascular Interventions 2012, 5: 157-165. PMID: 22354934, DOI: 10.1161/circinterventions.111.963876.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overBiomarkersFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHumansKidney Failure, ChronicMaleMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsReference StandardsSurvival AnalysisTroponin TConceptsGlycoprotein IIb/IIIa inhibitorsAcute coronary syndromeBaseline troponin elevationChronic kidney diseaseMajor adverse cardiac eventsTroponin elevationMyocardial infarctionBivalirudin monotherapyMajor bleedingCKD patientsCoronary syndromeBaseline troponinKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsLong-term clinical outcomesBaseline cardiac troponinBaseline troponin levelsDifferent antithrombotic regimensAdverse cardiac eventsACS patientsACUITY trialAntithrombotic regimensComposite deathRandomization arm
2011
Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh rate
2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.
Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky A, Winn ME, Schork NJ, Topol EJ. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Annals Of Internal Medicine 2010, 153: 425-34. PMID: 20921541, PMCID: PMC3786733, DOI: 10.7326/0003-4819-153-7-201010050-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAlgorithmsArea Under CurveChest PainCoronary AngiographyCoronary Artery DiseaseDiabetes MellitusFemaleGene ExpressionHumansMaleMiddle AgedProspective StudiesReverse Transcriptase Polymerase Chain ReactionRisk AssessmentROC CurveSensitivity and SpecificitySex FactorsYoung AdultConceptsObstructive coronary artery diseaseCoronary artery diseaseCoronary angiographyNondiabetic patientsQuantitative coronary angiographyArtery diseasePresence of CADClinical modelMore major coronary arteriesPeripheral blood gene expressionBlood-based gene expression testDiamond-Forrester methodMulticenter prospective trialMajor coronary arteriesChronic inflammatory disordersIndependent validation cohortReceiver-operating characteristic analysisBlood gene expressionReal-time polymerase chain reactionWhole blood testCardiac protein markersGene expression testNoninvasive imaging methodProspective trialRisk patients